BioWorld Today, the daily biopharmaceutical news source, delivers actionable intelligence on the biopharmaceutical industry. We report the breaking news and provide key perspective on hundreds of medicines in development, the biotechnology and pharmaceutical companies behind those therapeutic candidates, the business development transactions that drive the market, and the regulatory hurdles that both challenge and guard the process. With writers and editors stationed around the globe, BioWorld Today reports every business day on the news dramatically influencing the future of biotechnology.

Topics include:

•Strategic alliances, agreements, sales and mergers
•Therapeutic product development from early to late stage
•Capital sources and venture capital financing •Corporate financial and stock performance
•Biotech company advancements and setbacks •Scientific milestones in Alzheimer’s, infectious diseases, cancer, diabetes and many other therapeutic areas
•FDA and congressional actions affecting biopharma
•Global regulatory updates
•Profiles of new and mature biotech and specialty pharmaceutical firms in the U.S. , Europe, China and elsewhere
•Big pharma’s growing involvement in biotechnology

BioWorld Today is delivered first thing every business morning. We produce the BioWorld Midday Report early each afternoon, providing subscribers with an up-to-date look at current biotech and pharma news. In addition, our staff develops original, up-to-the-minute bulletins fired out to subscribers instantly as news warrants. We cover the giants of the industry, from Merck and GlaxoSmithKline to Amgen and Gilead Sciences, plus the hundreds of biotech industry start-ups and spin-offs that emerge every year. Biopharma executives, investors, attorneys, analysts – all use BioWorld Today to stay on top of the current news on scientific breakthroughs, new drug applications, biopharma licensing, M&A, development deals and more.